AMG-160 (Akapatamab) beim ASCO 2021 - mCRPC

AMG-160 (Akapatamab) beim ASCO 2021

26 Juni 2021
Safety and efficacy of AMG-160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).
Subudhi, SK et al.